Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TBPH
BuyPremium GrowerTheravance Biopharma, Inc. · Healthcare · United States · $885M · Avg Vol: $8M/d
COMPANY DESCRIPTION
Theravance Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. The company's competitive moat is built on its proprietary expertise in multivalent drug design, which optimizes therapeutic index and safety profiles. It operates as a specialized biotechnology player targeting respiratory and gastrointestinal diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.3M | 57.4M | 64.4M | 107.5M | 27.9% | 104.3M | 90.7M | 97.4M | -4.8% |
| EPS | 11.85 | -1.00 | -1.15 | 2.10 | -43.8% | 1.04 | — | — | — |
| Shares | 65.2M | 48.1M | 49.5M | 51.1M | -21.7% | 51.9M | — | — | — |
| Debt | 52.2M | 49.2M | 49.8M | 42.7M | -6.5% | 38.6M | — | — | — |
| Equity | 441.8M | 213.0M | 175.5M | 296.7M | -12.4% | — | — | — | — |
| Op CF | -187.0M | -27.0M | -11.5M | 238.5M | — | 53.7M | — | — | — |
| Inv CF | 1.2B | -32.7M | 12.3M | -105.3M | — | — | — | — | — |
| Fin CF | -758.8M | -198.9M | -2.5M | -3.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TBPH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TBPH | Theravance Biopharma, Inc.(you) | $885M | 76 | Buy |
| MDXG | MiMedx Group, Inc. | $656M | 73 | Buy |
| ABUS | Arbutus Biopharma Corporation | $1.0B | 84 | Strong Buy |
| MGTX | MeiraGTx Holdings plc | $1.3B | 68 | Buy |
| ZVRA | Zevra Therapeutics, Inc. | $687M | 91 | Strong Buy |
| AGEN | Agenus Inc. | $345M | 75 | Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $868M | 99 | Strong Buy |
| QTTB | Q32 Bio Inc. | $447M | 89 | Strong Buy |
| ANL | Adlai Nortye Group Ltd. | $890M | 49 | Hold |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%